<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114865</url>
  </required_header>
  <id_info>
    <org_study_id>J1713</org_study_id>
    <secondary_id>IRB00125679</secondary_id>
    <nct_id>NCT03114865</nct_id>
  </id_info>
  <brief_title>A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance</brief_title>
  <official_title>A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators primary objective is to determine the safety and toxicity of incorporating&#xD;
      blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance&#xD;
      setting for patients with CD19+-B-cell malignancies (Acute Lymphoblastic Leukemia [ALL],&#xD;
      Non-Hodgkin's Lymphoma [NHL]).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at two years post first treatment cycle</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of enrolled participants who receive BMT and Blinatumomab and are alive at two years post BMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who experience non-relapse mortality after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who experience progression-free survival after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who experience disease-free survival after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who experience overall survival after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who convert from MRD to no MRD after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Non Hodgkin Lymphoma</condition>
  <condition>Pre B-Cell Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>Post-alloHSCT Maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Cycle 1 - Days 1-7: 9 ug/day IV daily</description>
    <arm_group_label>Post-alloHSCT Maintenance</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Cycle 1 - Days 8-28: 28 ug/day IV daily</description>
    <arm_group_label>Post-alloHSCT Maintenance</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Cycle 2 - Days 1-28: 28 ug/day IV daily</description>
    <arm_group_label>Post-alloHSCT Maintenance</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV</description>
    <arm_group_label>Post-alloHSCT Maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Pre-B ALL, low and high grade NHL who underwent an alloHSCT using posttransplant CY&#xD;
             GVHD prophylaxis (Pt-Cy alone or combination with MMF/tacrolimus or sirolimus) as&#xD;
             follows:&#xD;
&#xD;
             A. Pre-B ALL patients in CR1 with high-risk features such as adverse cytogenetics&#xD;
             including t(9;22) or Ph-like ALL, t(4;11) or other MLL (KMT2A) rearrangements,&#xD;
             t(v;14q23)/IgH, complex karyotype (≥5 chromosomal abnormalities), hypodiploidy (&lt;44&#xD;
             chromosomes), low hypodiploidy (30-39 chromosomes)/near triploidy (60-68 chromosomes),&#xD;
             intrachromosomal amplification of chromosome 21 (iAMP21), high WBC count at&#xD;
             presentation (≥30,000), lack of achievement of complete remission after standard&#xD;
             induction chemotherapy (but achieved CR1 following salvage or consolidation), or&#xD;
             persistence of detectable disease after induction and consolidation (intensification)&#xD;
             or pre-transplant as documented on any of routine clinical tests (morphology, flow&#xD;
             cytometry, cytogenetics or molecular studies) OR all Pre-B ALL patients in second and&#xD;
             higher CR B. Low and high grade NHL following a nonmyeloablative (reduced-intensity&#xD;
             conditioning) transplant irrespective of pre-transplant disease status&#xD;
&#xD;
          2. Patients should be at least 60 but not more than 180 days from transplant with&#xD;
             documented count recovery (ANC &gt;1 x109/L, and non-transfused platelets &gt;30x109/L) and&#xD;
             no evidence of disease progression&#xD;
&#xD;
          3. ECOG performance status 0-2&#xD;
&#xD;
          4. Ability to give informed consent&#xD;
&#xD;
          5. In agreement to use an effective barrier method of birth control (hormonal or barrier&#xD;
             method of birth control; abstinence) to avoid pregnancy during the study and for a&#xD;
             minimum of 30 days after study treatment, for all male and female patients who are&#xD;
             fertile&#xD;
&#xD;
          6. Age ≥18 years&#xD;
&#xD;
          7. Patients may have received any number of prior regimens to achieve remission. Patients&#xD;
             previously treated with blinatumomab will be eligible as long as they did not&#xD;
             experience unacceptable toxicities with prior blinatumomab administration. If patient&#xD;
             was refractory (no response) to blinatumomab in the past, patient will be eligible if&#xD;
             there was no evidence of CD19 loss on leukemia cells.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Lack of engraftment (less than 85% donor DNA in bone marrow or peripheral blood after&#xD;
             allogeneic HSCT).&#xD;
&#xD;
          2. Active or untreated disease in central nervous system or testes&#xD;
&#xD;
          3. Patient has received chemotherapy or radiotherapy (with the exception of intrathecal&#xD;
             chemotherapy) within 2 weeks of starting blinatumomab. Patient could receive&#xD;
             intrathecal prophylactic chemotherapy within a week prior to starting blinatumomab.&#xD;
&#xD;
          4. Patients with active uncontrolled infection or uncontrolled intercurrent illness&#xD;
             including, but not limited to symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          5. Patients with prior history of severe (grade 3 or 4) acute GVHD or active severe&#xD;
             chronic GVHD even if resolved will not be eligible. Patients with history of active&#xD;
             acute GVHD (grade 2) and active moderate chronic GVHD who required steroids for the&#xD;
             treatment of GVHD will need to be off steroids for at least 4 weeks prior to treatment&#xD;
             start. (Topical steroids or physiologic adrenal replacement steroid doses are&#xD;
             allowed).&#xD;
&#xD;
          6. Patients requiring calcineurin inhibitors (i.e. tacrolimus or sirolimus) or other&#xD;
             systemic immunosuppressants (cyclosporine (CNI); methotrexate or similar) for GVHD&#xD;
             prophylaxis or treatment within 4 weeks prior to treatment start.&#xD;
&#xD;
          7. Inadequate end organ function defined as AST, ALT, and alkaline phosphatase &gt; 3X ULN,&#xD;
             bilirubin &gt;=1.5X ULN, or creatinine &gt;=2 mg/dL&#xD;
&#xD;
          8. Patients with Ph-positive ALL who are eligible for post-transplant TKI maintenance&#xD;
             based on a demonstrated sensitivity to TKIs pre-transplant (patients with known&#xD;
             intolerance or resistance to TKI will be eligible)&#xD;
&#xD;
          9. Evidence of progressive disease post-transplant&#xD;
&#xD;
         10. Women who are pregnant or lactating&#xD;
&#xD;
         11. Known hypersensitivity to blinatumomab&#xD;
&#xD;
         12. Patients with a concurrent active malignancy for which they are receiving treatment&#xD;
&#xD;
         13. Concurrent use of any other investigational drugs&#xD;
&#xD;
         14. Patient who have a history or presence of clinically relevant CNS pathology such as&#xD;
             epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia,&#xD;
             Parkinson's disease, cerebellar disease, psychosis, or other significant CNS&#xD;
             abnormalities. A history of treated CNS leukemia or lymphoma will be allowed if recent&#xD;
             imaging and CSF studies confirm the absence of active CNS disease at the time of study&#xD;
             entry&#xD;
&#xD;
         15. Weight &lt;45 kg&#xD;
&#xD;
         16. Patients receiving other post-transplant maintenance therapies&#xD;
&#xD;
         17. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis&#xD;
             B virus or hepatitis C virus (HCV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Gojo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Webster, MD</last_name>
    <phone>410-614-9106</phone>
    <email>jwebst17@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Webster, MD</last_name>
      <phone>410-614-9106</phone>
      <email>jwebst17@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone marrow</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>allogeneic</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>Blinatumomab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

